中国制造2025驱动下的医疗创新及跨国公司的启示（英文版）

2025-04-14 0 0 844.1KB 8 页 5.8玖币

侵权投诉

This paper considers the market, competitive and regulatory dynamics driving homegrown

innovation in healthcare in China, details the key “Made in China 2025” policy as it applies in

healthcare, and outlines the impact these developments are having on multinational

healthcare firms in China.

Context

During the past four decades, China’s economy has rocketed to become the

second-largest in the world. Now, however, it is facing different challenges:

The working-age population has peaked, employment costs continue to rise

rapidly, and the RMB has become stronger. As a result, China is finding it

difficult to maintain its stellar growth on the basis of being a low-cost

manufacturing center. In their efforts to avoid the middle income trap that affects many

emerging economies, China’s leading policymakers have focused on raising productivity and

bolstering innovation to upgrade China’s economy.

During the past decade, innovation, especially domestic innovation, has been gaining

attention and driving government and private investment into biopharmaceuticals, medical

technology and healthcare delivery.

In transitioning to a higher-value-added ecosystem, China’s government has introduced

healthcare system reforms in wide-ranging areas including government funding for research

and development, overhaul of market authorization requirements, product accreditations,

procurement evaluations, management of the distribution channel, pricing, and payment.

While these reforms are certainly intended to be beneficial in the domestic market, some

are seen as controversial — especially those with an industrial policy dimension where

China is sponsoring indigenous development of technologies that are destined to become

competitive in the global marketplace.

China’s government has unleashed round upon round of reform to promote healthcare

innovation (see Chart 1).

GPS Healthcare Quarterly

Innovation in China, “Made in China 2025” and

Implications for Healthcare MNCs

July 2018

Chart 1: Innovation regulations published over time

Note: Includes nine administrative regulations issued by the State Council and 153 other regulations issued by other

national departments

Source: CNKI, L.E.K. research and analysis

What is “Made in China 2025”?

The single most influential policy now driving innovation is “Made in China 2025”

(“MiC2025”), whose scope and scale is now becoming clear three years after launch. As a

result of “MiC2025”, foreign companies in the healthcare sector are re-evaluating their

business models, market positions, technologies and product pipelines for China. This report

will focus on “MiC2025” and its impact on multinational healthcare companies operating in

China.

Made in China

Today, China’s high-end drugs and medical products markets are dominated by

multinational companies (MNCs) equipped with innovative technologies, while domestic

companies mostly produce components for those systems or lower-quality products that

are not widely accepted outside China and developing markets.

In May 2015, the Chinese government unveiled “MiC2025”, a blueprint calling for

investment of as much as RMB 8 trillion

(~US$1.2 trillion) and intended to transform China

into a global high-end manufacturing powerhouse over the next decade. “MiC2025” is

broad-reaching and covers 10 high-technology fields — including biopharma and high-

http://www.scmp.com/news/china/economy/article/1814281/made-china-smart-revolution-blueprint.

文档加载中……请稍候！
如果长时间未打开，您也可以点击刷新试试。

下载文档到电脑，查找使用更方便

5.8 玖币 0人已下载

立即下载

摘要：

1Thispaperconsidersthemarket,competitiveandregulatorydynamicsdrivinghomegrowninnovationinhealthcareinChina,detailsthekey“MadeinChina2025”policyasitappliesinhealthcare,andoutlinestheimpactthesedevelopmentsarehavingonmultinationalhealthcarefirmsinChina.ContextDuringthepastfourdecades,China’seconomyhas...

展开>> 收起<<

中国制造2025驱动下的医疗创新及跨国公司的启示（英文版）.pdf

共8页,预览2页

还剩页未读，继续阅读

声明：本站为文档C2C交易模式，即用户上传的文档直接被用户下载，本站只是中间服务平台，本站所有文档下载所得的收益归上传人(含作者)所有。玖贝云文库仅提供信息存储空间，仅对用户上传内容的表现方式做保护处理，对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私，请立即通知玖贝云文库，我们立即给予删除！

中国制造2025驱动下的医疗创新及跨国公司的启示（英文版）

相关推荐

开通VIP享超值会员特权

作者详情

相关内容

热门标签

举报选择: